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A B S T R A C T
Background: Although most observational studies identify viral or bacterial pathogens in 50% or less of
patients hospitalized with community-acquired pneumonia (CAP), we previously demonstrated that a
multi-test bundle (MTB) detected a potential pathogen in 73% of patients. This study compares detection
rates for potential pathogens with the MTB versus the Biofire Pneumonia FilmArray panel (BPFA) multi-
plex PCR platform and presents an approach for integrating BPFA results as a foundation for subsequent anti-
biotic stewardship (AS) activities.
Methods: Between January 2017 to March 2018, all patients admitted for CAP were enrolled. Patients were
considered evaluable if all elements of the MTB and the BPFA were completed, and they met other a priori
inclusion criteria. The primary endpoint was the percentage of potential pathogens detected using the MTB
(8 viral and 6 bacterial targets) versus the BPFA (8 viral and 18 bacterial targets). Blood and sputum cultures
were performed on all patients. Two or more procalcitonin (PCT) levels assisted clinical assessments as to
whether detected bacteria were invading or colonizing.
Results: Of 585 enrolled patients, 274 were evaluable. A potential viral pathogen was detected in 40.5% with
MTB versus 60.9% of patients with BPFA with an odds ratio (95% CI) of 9.00 (4.12 to 23.30) p<0.01. A potential
bacterial pathogen was identified in 66.4% with the MTB vs 75.5% with the BPFA odds ratio (95% CI) of 2.09
(1.24 to 3.59), p 0.003). Low PCT levels helped identify detected bacteria as colonizers.








Compared to a standard multi-test diagnostic bundle, the sputum
Biofire\elsamp #x00AE; Pneumonia FilmArray\elsamp #x00AE;
multiplex platform, significantly increased the detection of poten-
tial viral and bacterial pathogens in hospitalized adult patients
with community-acquired pneumonia.
Summary
For hospitalized patients with CAP, the Biofire\elsamp #x00AE;
Pneumonia FilmArray\elsamp #x00AE; multiplex platform sig-
nificantly increased the number of patients with detectable
viral and bacterial potential pathogens and, thereby, provided
key data for AS activities.
1. INTRODUCTION
Pneumonia is the leading cause of death due to infection in the
United States with an estimated 1.2 million annual hospitalizations
(Self et al., 2017). Management of community-acquired pneumonia
(CAP) entails empiric antibiotic therapy that targets the most likely
bacterial pathogens. The American Thoracic Society-Infectious Dis-
eases Society of America CAP guidelines reserve microbiologic testing
for patients with severe CAP (Metlay et al., 2019). Further, “rapid,
cost-effective, sensitive, and specific diagnostic tests to identify
organisms causing CAP have potential to improve routine care by
supporting the use of targeted therapy . . .” (Metlay et al., 2019)
A benchmark study reported that microbiologic testing identified
the microbiologic etiology in only 853 of 2259 (38%) hospitalized CAP
patients (Jain et al., 2015). To improve this diagnostic yield, we
reported that a multi-test bundle (MTB) consisting of sputum and
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blood bacterial cultures, polymerase chain reaction (PCR) testing of
nasopharyngeal swabs (NP) samples by the multiplex Biofire (Bio-
fire Co., Salt Lake City, Utah) Respiratory FilmArray panel, anterior
nasal swab PCR for Staphylococcus aureus, nasopharyngeal swab for
Streptococcus pneumoniae, and urine antigen testing for S. pneumo-
niae and Legionella pneumophila detected a potential bacterial and/or
viral pathogen in 73% of patients (Gilbert et al., 2016, Carvalho Mda
et al., 2007). The feasibility of this approach was hampered by long
turn-around times (TAT) for multiple MTB components, and the fail-
ure of the MTB to detect common potential bacterial pathogens, such
asMoraxella and Haemophilus species.
The Biofire Pneumonia FilmArray (BPFA) panel probes sputum
samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour
TAT. However, the performance of BPFA as compared with multi-ele-
ment testing, such as MTB, has neither been evaluated in large stud-
ies, nor integrated into clinical practice to identify invasive vs
colonizing pathogens. Herein, we compare the detection of potential
viral and bacterial pathogens with MTB as compared with BPFA. We
hypothesized that the BPFA would detect more potential viral and
bacterial pathogens than MTB. We also present our approach to inte-
grating BPFA results into clinical practice by eliminating unnecessary
tests and serving as the basis of antibiotic stewardship (AS) activities.
2. MATERIALS ANDMETHODS
2.1. Study Patients
The study was registered with clinicaltrials.gov (NC02580384) as
a prospective, non-blinded comparison of pathogen detection with
patients as their own controls was conducted at Providence Portland
Medical Center, a 480-bed community teaching hospital in Portland,
Oregon between January 2017 and March 2018 and approved by the
Privacy Board and the Institutional Board (IRB) that waived informed
consent. Subjects were identified from adults (over the age of 18)
presenting to the Emergency Department with respiratory symptoms
diagnosed by emergency physicians as CAP based on their usual clini-
cal practice. All patients were given a consecutive study number and
their clinical data were entered into an online database (FileMaker
13, Claris International Inc, Santa Clara, CA). Within two days, a
study investigator (DNG or JEL) reviewed the database to ascertain if
the patient was evaluable based on the presence of all inclusion
criteria:
1. Production of sputum, or sputum equivalent (e.g. endotracheal
tube aspirate, bronchoalveolar lavage) for testing.
2. Availability of all elements of the MTB and BPFA (Sputum or spu-
tum equivalent) and blood samples for PCT levels.
3. Absence of any extrapulmonary infection that required antibiot-
ics (e.g., pyelonephritis).
4. No transition to comfort care within 24 hours of admission.
5. No history of a witnessed aspiration of gastric contents.
6. Diagnosis not changed by treating physicians to a non-infectious
disease (e.g., pulmonary edema) within 48 hours.
2.2. Specimen collection
Emergency Department (ED) nurses collected two blood culture
samples and expectorated or hypertonic saline-induced sputum (or
endotracheal aspirate) for BPFA; in addition, sputum was submitted
for culture. For MTB, nasopharyngeal swab samples were submitted
for the BioFire Respiratory FilmArray panel and lab-generated PCR
for S. pneumoniae (Carvalho Mda et al., 2007); anterior nasal swab for
S. aureus PCR (BD Max SR), and urine for antigen detection (Binax-
now, Abbott Labs, Abbott ParK, IL) of S. pneumoniae and L. pneumo-
phila (Table 1). Blood was collected for PCT testing (Used Vidas B.R.A.
H.M.S instrument and PCT reagents from Biomerieux, Durham, NC)
with PCT retesting 4-6 hours later. A rapid response laboratory adja-
cent to the ED received all samples.
2.3. Data collection
The laboratory entered MTB results into the electronic medical
record (EMR), and study investigators re-entered EMR data in the Fil-
eMaker database. Being investigational, the BPFA results were
entered by investigators into the study database. Three authors
(DNG, JEL, SF) verified the accuracy of all transcribed data.
2.4. Study objectives
The primary objective was to determine if BPFA improved detec-
tion rates for potential viral and bacterial pathogens as compared
with MTB. We also present an approach to integrating BPFA results
into clinical practice aided by PCT testing. Lastly, we suggest that use
of BPFA may eliminate the need for selected diagnostic tests in the
current MTB.
2.5. MTB and BPFA Test Components
Table 1 lists the components of the MTB and BPFA entered into
comparative analyses. See Table 2 for components of the Biofire Respi-
ratory and Pneumonia FilmArray panels used in MTB and BPFA.
2.6. Clinical Categorization and Adjudication
The FileMaker database calculated a pneumonia severity index
(PSI) for each patient (Fine et al., 2020). To assess the clinical impor-
tance of detected pathogens, patients were divided into four catego-
ries (Table 3) based on their clinical and laboratory presentation, PCT
test results, and likelihood based on clinical judgment (adjudication)
as to whether detected pathogens were colonizing or invasive.
In adults with CAP, detection of a potential viral respiratory path-
ogen is accepted as compatible with the etiology of the patient’s inva-
sive infection as the frequency of asymptomatic colonization is very
low. In a prospective controlled detection trial in adult CAP patients,
detection of influenza, hMPV, and RSV “probably indicate an etiologic
role.” Detection of other respiratory viruses, especially in children,
requires further study (Self et al., 2016).
The biomarker procalcitonin (PCT) was used to assist in the clini-
cal decision as to whether a detected virus and/or bacteria was a
commensal. PCT serum levels do not increase with pure viral infec-
tion but do increase with invasive bacterial infection or the combina-
tion of viral and bacterial disease (Gilbert, 2020, Gilbert, 2017).
Table 1
Components of Multi-Test Bundle and BioFire Pneumonia FilmArray Testing
Multi-Test Bundle BioFire Pneumonia FilmArray
Blood cultures x 2 Blood cultures x 2
Sputum culture if sputum purulent Sputum culture if sputum purulent
NP swab for Biofire Respiratory
FilmArray**
Sputum* for Biofire Pneumonia
FilmArray**
Nasal swab for Staphylococcus aureus
PCR (BD Max SR)
NP swab for Streptococcus pneumo-
niae PCR
Urine for Streptococcus pneumoniae
and Legionella pneumophila anti-
gens (Binaxnow)
NP = nasopharyngeal, PCR = polymerase chain reaction
* sputum or sputum equivalent (ie, endotracheal aspirate, bronchoalveolar lavage)
** Organism targets for BioFire FilmArray panels listed in Table 2.
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The BPFA panel includes genomic semi-quantitation of 15 of 18
bacterial targets with the premise that higher bacterial “loads”would
be consistent with invasive infection. However, concordance
between genomic semi-quantitation and sputum culture CFU/ml is
reported between 40 and 54% and the degree of concordance varied
by organism (Biofire 2020, Lee et al., 2019, Murphy et al., 2020). For
these reasons, we elected to not use the BPFA semi-quantitation
result in the adjudication of positive pathogen detection.
2.7. Cost Considerations
We determined the costs of BPFA versus all elements in the MTB
based on 2017-2018 cost data.
2.8. Statistics
The performance between MTB and the BPFA was compared
based on the number of pathogen species (bacterial and/or viral)
detected in each patient by the two methods, using the paired t-test
and Wilcoxon signed rank test. The same analysis was repeated for
the number of bacterial species detected and for the number of viral
species detected.
McNemar test assessed the difference in the proportions of
patients detected with pathogen(s) (combined bacterial plus viral,
bacterial, viral, and selected individual specific pathogen species)
between MTB and BPFA.
The detection of individual specific pathogen species by the BPFA
method was evaluated and presented as positive percent agreement
(PPA) and negative percent agreement (NPA) against the MTB
method; p-value <0.05 considered statistically significant. The R sta-
tistical program (www.r-project.org, R Foundation for Statistical
Computing, Vienna, Austria) performed all analyses.
3. RESULTS
Of 585 enrolled patients, 274 (47.2%) were evaluable and 311
were excluded (Figure 1). Non-evaluability most commonly resulted
from a final diagnosis other than CAP [159 of 311 (51.1%)], not obtain-
ing a sputum or equivalent for BPFA [139 of 311 (44.7%)], and/or
Table 2
Comparison of organism targets in the Biofire Respiratory FilmArray and the Biofire Pneumonia FilmArray Panels. The Respiratory Panel requires a nasopharyngeal swab and the















Adenovirus X X Bordetella pertussis X O Acinetobacter calcoaceticus-bau-
mannii complex
O X
Coronavirus** X X Chlamydophila pneumonia X X Enterobacter cloacae complex O X
Human metapneumovirus X X Legionella pneumophila O X Escherichia coli O X
Human rhinovirus/enterovirus X X Mycoplasma pneumoniae X X Haemophilus influenzae O X
Influenza A X X Klebsiella aerogenes O X
Influenza B X X Klebsiella oxytoca O X
Parainfluenza virus X X Klebsiella pneumoniae group O X
Respiratory syncytial virus X X Moraxella catarrhalis O X
Proteus spp O X
Pseudomonas aeruginosa O X
Serratia marcescens O X
Staphylococcus aureus O X
Streptococcus agalactae O X
Streptococcus pneumoniae O X
Streptococcus pyogenes O X
* Sputum or sputum equivalent (ie, endotracheal aspirate or BAL)
** Includes 4 strains of coronavirus, but not SARS-CoV-2
Table 3
Clinical Classification of Patients Based on Integration of Test Results with Clinical
Judgment
Uninfected: No evidence of CAP
Post-admission clinical, laboratory, and imaging studies document an alterna-
tive non-infectious diagnosis: e.g., congestive heart failure.
Pure Bacterial Pneumonia
Proven: A compatible clinical syndrome (fever, cough, new pulmonary infil-
trates, elevated white blood count) with detection of only bacterial patho-
gen(s) by one or more of: Biofire Respiratory FilmArray , NP S. pneumoniae
PCR, nasal swab for S. aureus PCR, urine antigens, sputum and/or blood cul-
ture, or BPFA.
Presumptive: Clinical CAP syndrome with compatible chest radiographic
abnormalities without detection of a potential bacterial pathogen by any of
the same tests listed in the last paragraph. A PCT level ≥0.25 ng/ml with no
other explanation was interpreted as presumptive evidence of invasion by
an undetected bacterial pathogen.
Pure Viral Pneumonia
Presumptive: High probability of viral pneumonia based on compatible clinical
presentation, detection of a virus by the BioFire Respiratory FilmArray or
BPFA absent detected bacterial pathogen by FilmArray , and serum PCT
level <0.25 ng/ml.
Viral and Bacterial Co-Infection
Presumptive: Detection of a virus by either the BioFire Respiratory
FilmArray or BPFA. In addition, detection of a bacterial pathogen in sputum
and/or blood cultures, urine antigen tests, the Biofire Respiratory
FilmArray , the BPFA, the nasal swab for S. aureus and/or the NP PCR for S.
pneumoniae.
Pneumonia of Unclear Etiology
Clinical criteria for CAP but no bacterial or viral pathogen detected by any test
and no non-infectious disease diagnosed.
NP = nasopharyngeal; PCR = polymerase chain reaction; PCT = procalcitonin;
BPFA = BioFire Pneumonia FilmArray Figure 1. Flow diagram of 585 enrolled patients
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incomplete MTB results [13 of 311 (4.2%)]. The 274 (47.2%) evaluable
patients were divided into four categories based on detected poten-
tial pathogens:
1. Virus only: 31 (11.3%)
2. Bacteria only: 87 (31.8%)
3. Virus and bacteria detected: 143 (52.2%)
4. No potential pathogen detected: 13 (4.7%)
This older patient population had many co-morbidities, and 64.2%
had PSI scores >91, Table 4. BioFire results returned within 2 hours,
and other PCR and urine antigen tests returned from 2 to 24 hours.
3.1. MTB and BPFA Pathogen Detection Rates
The proportion of all patients detected by MTB or BPFA with poten-
tial bacterial pathogens (§ a viral pathogen) or potential viral pathogens
(§ a bacterial pathogen) are shown in Table 5 along with the aggregate
proportion of patients detected with any potential pathogen (bacterial
and/or viral pathogens). The BPFA panel as compared with MTB
detected more patients with bacterial pathogens (75.5% vs 66.4%,
p=0.003) and viral pathogens (60.9% vs 40.5%, p=<0.001). Significantly
more patients were detected by BPFA as having any potential pathogen
(viral, bacterial or both) (90.6% vs 80.9%, p=0.001), Table 5.
3.2. Comparison of Detection Rates for Specific Bacterial and Viral
Pathogens
The BPFA outperformed the MTB in identifying all patients with
Haemophilus influenzae, Moraxella catarrhalis, Streptococcus agalactiae,
and Enterobacteriaceae, p ≤0.001 (Figure 2). Detection rates for S.
pneumoniae varied widely in the 274 patients between individual ele-
ments of MTB (Figure 3). The BPFA detected S. pneumoniaemore often
(in 78 patients, 28.5%), than any individual component in MTB but not
with the composite MTB (Figure 3).
S. aureus was detected by nasal swab PCR in 94 of 274 (34.3%)
patients vs. 71 of 274 (25.9%) by BPFA, p=0.002. Six patients (all
detected by BPFA probe of sputum) had S. aureus bacteremia, three
methicillin-sensitive S. aureus (MSSA) and three methicillin-resistant
S. aureus (MRSA).
Only one patient had a positive urine antigen test for Legionella
pneumophila.
The BPFA detected significantly more patients with potential viral
pathogens (coronavirus, hMPV, influenza, parainfluenza, and rhinovi-
rus) than the BioFire Respiratory FilmArray component of MTB
(Figure 4). Influenza virus was detected in 61 (22.3%) with BPFA as
compared to 39 (14.2%) with MTB, p <0.001. The number of patients
with one or more detectable viruses increased from 41% with MTB to
61% with BPFA, p<0.001.
3.3. Positive Blood Cultures
Of 274 CAP patients, 22 (8%) had positive blood cultures deemed
pathogens rather than contaminants. The same organism was
detected in the sputum culture in 9 of the 22 (41%) patients. On the
other hand, S. aureus by sputum BPFA in 17 of the 22 (77%) patients.
S. pneumoniae was identified in the blood of 10 patients, S. aureus
in 6, S. pyogenes in 2, and Enterobacter cloacae, E. coli, S. agalactiae,
and Aerococcus viridans each in one patient. A concomitant viral path-
ogen was detected by BPFA in 10 of the 22 patients with positive
blood cultures.
3.4. Multiple Pathogen Detection
The superiority of the BPFA as compared with MTB in detecting
co-infections is reported in Table 6. In one extreme example, BPFA
detected 1 virus (RSV) and 5 bacterial species (E.coli, P. aeruginosa, K.
pneumoniae, S. marcescens, and MRSA) while the MTB detected no
virus and 3 bacteria (P. aeruginosa, E. coli, and MSSA).
Table 4
Demographics and Pneumonia Severity of 274 evaluable patients
Mean (SD) Median (IQR)
Age 66.3 (16.6) 68 (56,79)
Weight (kg) 77.2 (28.0) 72.6 (59.4, 88.5)
Gender female, n (%) 126 (46.0%)
Comorbidity n (%)
Alcoholism 21 (7.7%)
Cerebrovascular disease 33 (12.0%)
Chronic liver disease 22 (8.0%)
Congestive heart failure 65 (23.7%)
COPD 114 (41.6%)
Diabetes mellitus 84 (30.7%)
Illicit drug use 46 (16.8%)
Malignancy 55 (20.1%)
Obesity (BMI>30) 66 (24.1%)
Renal insufficiency(CrCl<2) 11 (4.0%)
Pneumonia Severity Index n (%)
____≤70 Risk classes I & II 46 (16.8)
____71-90 Risk class III 52 (19.0)
____91-130 Risk class IV 94 (34.3)
____>130 Risk class V 82 (29.9)
Table 5
Number of patients with bacterial, viral, or any (bacterial and/or viral) potential pathogens detected by MTB and BPFA
Bacteria MTB BPFA Effect Measure p-value*
Any bacteria, patient No. (%) 182 (66.4%) 207 (75.5%) OR (95% CI) = 2.09 (1.24,3.59) 0.003
Number of bacterial species per patient
Mean (SD) 0.92 (0.82) 1.35 (1.19) Diff (95% CI=0.43(0.30,0.56) <0.001
Median (IQR) 1 (0,1) 1 (1,2) NA <0.001
Virus
Any virus, patient No.(%) 111 (40.5%) 167 (60.9%) OR (95%CI)=9.00(4.12,23.30) <0.001
Number of virus species per patient
Mean (SD) 0.43 (0.55) 0.68(0.61) Diff (95%CI)=0.25 (0.18,0.31) <0.001
Median IQR) 0 (0,1) 1 (0,1) NA <0.001
Combined bacteria and virus species
Any pathogen detected, patient No.(%) 224 (80.9%) 251 (90.6%) OR (95%CI)=3.33 (1.71, 6.98) <0.001
Number of pathogen species per patient
Mean (SD) 1.35 (0.94) 2.03 (1.27) Diff (95%CI)=0.68 (0.53,0.83) <0.001
Median IQR) 1 (1,2) 2 (1,3) NA <0.001
MTB =Multi-test bundle; BPFA = BioFire Pneumonia FilmArray
* p-value was based on McNemar test for odds ratio, paired t-test for mean difference, and Wilcoxon signed rank test for distribution
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Figure 2. Comparison of MTB versus BPFA for detecting number of patients with potential bacterial pathogens, with or without detectable virus. Some patients were detected with
more than one bacterial species.
Figure 3. Comparison of number of patients detected with Streptococcus pneumoniae by individual elements of the multi-test bundle vs the BioFire Pneumonia FilmArray . Some
patients had more than one test element positive for S. pneumoniae. PCR denotes polymerase chain reaction.
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3.5. Potential Role of Serum PCT Levels
Detected pathogens are either colonizing or invading and stimu-
lating host innate immune inflammatory response. All 274 evaluable
patients had a clinical syndrome consistent with pneumonia; one or
more potential pathogens were detected in 261. As the clinical syn-
dromes lack discriminating features, we assessed whether the bio-
marker PCT could help adjudicate whether the detected potential
virus and/or bacteria were colonizing or invading.
PCT levels are a marker of activation of the host innate immune
inflammatory response by invading bacterial pathogens but not by
pathogenic respiratory viruses (Gilbert, 2020, Gilbert, 2017). PCT lev-
els increase in the presence of concomitant invasive disease by a virus
and/or bacteria.
We divided our patients into four categories depending on the
pathogens detected (Figure 5). By convention, a serum PCT elevation
of ≥0.25 ng/ml is selected as a clinically meaningful increase.
In 87 of 274 patients, only potential bacterial pathogens were
detected by the MTB and/or BPFA of which 69 (79.3%) had PCT levels
≥0.25 ng/ml, a result consistent with invasive bacterial infection. In
the remaining 18 (20.7%) patients, the PCT of <0.25 ng/ml was con-
sidered consistent with colonization by the detected bacteria.
For 143 patients, both viral and bacterial pathogens were detected
by MTB and/or BPFA. Ninety-six (96) (67.1%) of these patients had
PCT levels ≥0.25 ng/ml, which was interpreted as consistent with
bacterial and viral co-infection. Forty-seven (47) patients (32.8%) had
PCT values <0.25 ng/ml consistent with bacterial colonization and
viral infection.
For 31 patients, only a potential viral pathogen was detected. In 11
(35.5%) the PCT level was ≥0.25 ng/ml consistent with viral infection
and a superimposed, but undetected, bacterial pathogen.
The range of PCT levels in the 13 patients with no detected patho-
gens may reflect the presence of undetected viral and/or bacterial
pathogens.
3.6. Comparative Cost of MTB vs Test Bundle with BPFA
Our laboratory estimated the costs for MTB as compared with the
projected cost of a new test bundle anchored by the BPFA, Table 7.
Results indicate cost savings for the BPFA approach partially because
three nasal swab PCRs and the two urine antigen tests would no lon-
ger be needed.
4. DISCUSSION
Our results demonstrate, in adult patients hospitalized for CAP,
that the Biofire Pneumonia FilmArray (BPFA) detected more
Figure 4. Comparison of MTB versus BPFA for detecting number of patients with potential viral pathogens, with or without detectable bacteria Some patients were detected with
more than one viral species.
Table 6
Comparative detection of multiple bacterial and viral species with BPFA versus MTB





Only virus 1 24 25
2 1 5
Only bacteria 1 43 37
2 17 21
≥3 5 19
Virus (V) and Bacteria (B) 1 (V) + 1 (B) 54 62
1 (V) + 2 (B) 10 30
1 (V) +≥3 (B) 3 20
2 (V) + 3 (B) 5 12
+Representative data. Less frequent combinations are not included
* MTB: Multi-test bundle; BPFA: Biofire Pneumonia FilmArray
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patients with potential viral and bacterial pathogens (90.6%) than the
MTB (80.9%), the latter having been our standard of practice
(Gilbert et al., 2016).
BPFA sputum detection of 6 of the 7 respiratory viruses was statis-
tically more frequent than testing for the same 7 viruses with the
nasopharyngeal Biofire respiratory FilmArray panel which is part
of the MTB.
The higher yield with the BPFA may reflect higher viral loads in
the lower as compared with upper airways (Jeong et al., 2014, Wun-
derink, 2017). Alternatively, the higher yield may be due to differen-
ces in the viral primers used in the BPFA vs the primers in the Biofire
respiratory FilmArray (BioFire FilmArray User Instruction book-
lets).
For bacterial pathogens, BPFA detected more patients with 4 of
the common pathogens that cause CAP. Notably, BPFA detected more
patients with S. pneumoniae than individual urine antigen testing,
nasal PCR, or sputum and blood cultures although statistically equiv-
alent to the composite MTB results.
S. aureus was the only bacterium detected more frequently using
the the nasal swab PCR in the MTB vs the sputum BPFA, p=0.001. The
difference may result from differences in the PCR primers used for
the nasal swab PCR in the MTB as compared with BPFA primers. In
addition, replication of S. aureus is enhanced at 35°C (anterior nares)
vs 37°C in the lower airway source of sputum sent for BPFA (Matoos-
Mora et al., 1988, Milne et al., 1987).
An emerging body of evidence supports the use of PCR for the
detection of etiologic pathogens for CAP. Previous studies combined
cultures of sputum and blood, urine antigen detection, and NP multi-
plex platforms that primarily focused on viral pathogens and a few
atypical bacteria. The reported detection rates for pathogens have
varied between 38-53% of patients (Self et al., 2017, Jain et al., 2015,
Stockmann et al., 2018, Musher et al., 2013, Musher et al., 2017).
First generation multiplex PCR respiratory panels only
detected three atypical bacteria. Cultures and antigen detection
are needed to detect common pneumonia pathogens: i.e., S. pneu-
moniae, H. influenzae, M. catarrhalis and others. We generated a
MTB that included PCR probes for S. pneumoniae and S. aureus
plus the Biofire Respiratory FilmArray panel which includes 7
viruses (Gilbert et al., 2016).
Traditional sputum cultures and antigen detection may miss bac-
terial pathogens obscured by in vitro overgrowth of normal oral flora
and/or suppression of growth by empiric antibiotic therapy. Hence,
we compared the present study to determine if the BPFA, with the
18-targeted bacterial targets, would increase detection as compared
to our standard of care (SOC) MTB.
4.1. Study of BPFA vs SOC by Others
Other studies have compared pathogen detection by BPFA with
standard of care (SOC) diagnostics. The SOC is not standardized from
study to study but includes some combination of cultures of sputum
and blood, urine antigens and nasopharyngeal swabs for multiplex
PCR panels that most often focus on seasonal respiratory viruses.
In representative studies, the BPFA panel detected a viral and/or
bacterial potential pathogen in 47.4 to 72% of the CAP patients
(Lee et al., 2019, Murphy et al., 2020, Webber et al., 2020,
Figure 5. Box plot of distribution of serum procalcitonin levels in each of the 4 categories of pathogen detection. Each dot represents a single patient. The red line marks a serum
procalcitonin level of 0.25 ng/ml
Table 7
Comparative laboratory cost of MTB vs projected cost of BPFA bundle
Test MTB, $ BPFA, $
Urine antigen No need for urine antigens
Legionella 30.00
S. pneumoniae 19.00
Nasal swabs − PCRs No need for nasal swabs
S. aureus 42.00
S. pneumoniae 25.00
PCR “resp panel” 91.00
Biofire Pneumonia FilmArray 180.00
Sputum C&S 8.23 8.23
Blood culture x 2 9.80 9.80
Tech x 1 hr @$36.50/hr 36.50
Tech x 1/2 hr @ 36.50/hr 18.00
PCT @ $23 ea x 2 46.00 46.00
SUBTOTAL 307.53 262.03
Overhead @ 30% 92.00 79.00
TOTAL 399.53 341.03
$ = Dollars: represents estimated cost as per 2018
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Buchan et al., 2020). The number of patients varied from 595 to 1682.
Patient population, comorbidities, severity of illness, season of the
year, variations in PCR primers are a few of many pertinent variables.
Akin to our results, Webber et al detected potential bacterial
pathogens in 60 patients by both SOC and BPFA plus an additional 92
detections of bacteria by the BPFA (Webber et al., 2020). Buchan et al
reported similar results from 259 adult patients (Buchan et al., 2020).
Gadsby’s research group has developed a PCR pneumonia panel
with probes for 13 bacteria and 7 viruses. In 323 adult CAP patients, a
potential bacterial pathogen was identified in 81.1%. H. influenzae
and S. pneumoniae were the most frequently identified bacteria
(Gadsby et al., 2016).
The BPFA is not the only commercial rapid syndromic molecular
test panel for pneumonia pathogen identification (Noviello and
Huang, 2019, Poole and Clark, 2020). The Curetis Unyvaro Hospital-
ized Pneumonia panel is FDA-approved and includes 17 bacterial, 3
atypical bacteria, 1 fungal, and 19 resistance genes but no viral tar-
gets. There are at least 4 other commercial entities developing pneu-
monia diagnostic panels (Poole and Clark, 2020).
4.2. Colonization versus Infection
Several studies report increased detection of potential viral and bac-
terial pathogens in lower respiratory secretions of CAP patients when
SOC diagnostics are compared to use of the BPFA (Lee et al., 2019,
Murphy et al., 2020, Webber et al., 2020, Poole and Clark, 2020). The
positive and negative percent agreements concur with some variation
as expected with variations in the SOC tests employed.
Rapid, sensitive, and specific identification of potential bacterial
pathogens is a premise of improving the care of CAP patients. In the-
ory, identification of a pathogen will allow switching from empiric
antibiotic therapy to more focused specific therapy. Before switching,
clinicians need to consider whether the detected bacteria are only
colonizing and not a concern.
The BPFA platform provides a semi-quantitative number of bacte-
rial genomes/ml present. Traditional indicators of bacterial invasion
correlate with greater the numbers of bacteria, but patients with
selected co-morbidities may be only colonized and yet have a high
density of bacteria: e.g., cystic fibrosis, bronchiectasis, colonized tra-
cheostomy. Growth characteristics of organisms are another variable.
Antibiotic therapy can influence bacterial density. Hence, we elected
to not utilize the results of bacterial quantitation in our adjudication
of whether the detected bacteria are colonizing or invading.
We elected to use the serum biomarker procalcitonin (PCT) to
assist in the assessment of whether detected bacteria were colonizing
or invading. Elevations of serum PCT indicate activation of innate
immunity (Gilbert, 2020, Gilbert, 2017). PCT gene activation does not
occur with pure viral infection but promptly increases in response to
invasion by bacteria to include dual infection with a virus
(Branche et al., 2019, Schuetz et al., 2017, US Food and Drug Adminis-
tration 2017). The other variables that influence PCT serum levels; e.
g., impaired renal function, are known (Gilbert, 2020).
Jain and Pavia point out that the “holy grail” would apply molecu-
lar diagnostics to lung tissue (Jain and Pavia, 2016). In the absence of
lung tissue, we integrated BPFA results with the clinical presentation
and PCT test results to characterize with an a priori classification sys-
tem the likelihood of CAP due to bacterial and/or viral pathogens
(Table 3). This approach allows clinicians to focus the antimicrobial
regimen and promote antibiotic stewardship.
Based on previous research, we selected PCT serum levels of
≥0.25 ng/ml as consistent with activation of an innate immune
response by invasive bacteria (Branche et al., 2019, Schuetz et al.,
2017). PCT levels of <0.25 ng/ml were interpreted as consistent with
colonization (negative predictive value for invasive bacterial infection
is >90%) (Self et al., 2017, Gilbert, 2017, Stockmann et al., 2018). The
potential value of pathogen detection coupled to PCT levels is
acknowledged in multiple publications (Branche et al., 2019,
Schuetz et al., 2017, US Food and Drug Administration 2017, Jain and
Pavia, 2016, Wunderink et al., 2020). A recent economic model sup-
ported use of PCT serum levels as a way to reduce hospital costs,
decrease the risk of antibiotic resistance and Clostridium difficile
infections, and enhance clinical decision-making beyond clinical
judgment and heuristic approaches (Mewes et al., 2020).
4.3. Suggested Revised Multi-Test Bundle
The diagnostic yield of BPFA creates an opportunity to simplify
diagnostic testing for CAP. The BPFA has PCR primers for all Legionella
species causing disease in humans suggesting elimination of the
urine antigen test for L. pneumophila. Also, the urine antigen test and
NP PCR for S. pneumoniae may be eliminated because BPFA outper-
formed both. The low yield of blood cultures compared to BPFA sug-
gests they can be reserved for ICU patients (Metlay et al., 2019). Of
note, nasal swabs for S. aureus PCRmay remain an optional test added
to BPFA as nasal samples were 9% more sensitive than sputum sam-
ples submitted to BPFA. Sputum cultures remain necessary to provide
antibiotic susceptibility testing of detected bacteria.
A new test bundle would include BPFA, sputum culture and sensi-
tivity, blood cultures for the critically ill, and perhaps nasal S. aureus
PCR. Two (2) PCT levels 4-6 hours apart for their high negative pre-
dictive value and to help discriminate between infection and coloni-
zation. This bundle replaces traditional testing, which may take 1-
2 days to complete vs a bundle anchored by BPFA that takes less than
2 hours. Moreover, this proposed bundle decreases the cost of testing
(Table 7) and, in theory, can reduce antibiotic consumption, and
shorten length of hospitalization (Buchan et al., 2020).
4.4. Limitations
Patients inability to provide sputum and the difficulty of ED physi-
cians in this single center study to make an accurate diagnosis of CAP
excluded a majority of patients from the study. To avoid excluding
patients from BPFA testing, studies are needed to assess the potential
value of oropharyngeal swab specimens in lieu of sputum for testing,
as has been investigated for children (Wang et al., 2019). Only 13
patients were excluded because of incomplete test results beyond
failure to collect sputum. Second, despite the large panel size, a fail-
ure of the PCR panels to detect bacteria or virus does not exclude the
presence of an undetected virus and/or bacteria. Third, without sys-
tematic antibody seroconversion testing, we could not provide defi-
nite differentiation between invasive viral disease vs viral
colonization. However, protracted viral colonization of adults is rare.
Lastly, we did not document the influence of rapid pathogen detec-
tion on antibiotic therapy, antibiotic adverse events to include C. dif-
ficle infection, antibiotic resistance, or need for patient isolation.
5. Conclusion
For hospitalized adult patients with CAP, the BPFAmultiplex platform
detected significantly more common viral and bacterial potential patho-
gens as compared to a MTB. Serum PCT levels can help in the judgement
as to whether detected bacteria are colonizing or causing infection.
Future studies are needed to critically assess the influence of
enhanced pathogen detection on antibiotic usage, prevalence of anti-
biotic adverse effects and antibiotic resistance, and other facets of
antimicrobial stewardship
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